Drugs / Plasma Rich in Growth Factors (PRGF)
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00743873 | Jan 2008 → Feb 2009 | congenital patella dislocation | Meir Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT00743886 | Jan 2008 → Feb 2009 | tibial collateral ligament bursitis | Meir Medical Center | Withdrawn | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06715085 | Jan 2025 → Feb 2026 overdue | musculoskeletal system disorder | Biotechnology Institute IMASD | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06975683 | May 2025 → May 2026 overdue | ovarian dysfunction | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasma Rich in Growth Factors (PRGF) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00743873 ↗ |
| Known as | PRGF | “Plasma Rich in Growth Factors (PRGF)” NCT06975683 ↗ |
| Route | Intramuscular | “US guided IM injection 3-6mg” NCT00743873 ↗ |